The importance of scientifically assessing vapes, heated tobacco and nicotine pouches
Scientific scrutiny is often overlooked in public discussions around next-generation products (NGP) like vapes, heated tobacco, and nicotine pouches. Yet clear and robust manufacturing, product stewardship, and scientific substantiation processes should be in place ensure they meet consumer expectations. To support this, Imperial Brands Science has developed a multi-stage scientific assessment framework (SAF) to evaluate NGP throughout their lifecycles.
Libby Clarke, Scientific Substantiation & Engagement Lead, explains how this approach helps ensure NGP are assessed in a rigorous and science-led way.
Comprehensive scientific assessment of the relative risks of NGP compared to cigarette smoking should form the basis of risk-proportionate, evidence-based regulation. The SAF is aligned with guidelines provided by leading global public health authorities and regulators. It consists of six stages: product characterisation, biological science, clinical science, perception and behavioural science, computational science and post-market surveillance.
The six steps explained
Product characterisation science is the first essential stage before further research commences. It includes risk assessment, product quality, aerosol chemistry and indoor air quality studies. At this stage, manufacturers demonstrate that NGP contain fewer and lower levels of harmful chemicals than those found in cigarettes[i]. An example of research in this area of the SAF can be found here.
Biological science provides the first indication of a product’s impact on consumers. Laboratory studies assess product safety and how exposure affects human cells compared to cigarette smoke, while reductions in harmful chemicals in NGP translate into reduced biological measures of in-vitro toxicity in human cells. Imperial’s work combines data gathered via recognised regulatory testing methods with cutting-edge TT21C-inspired[ii] research. Read more about our approach – titled Alternatives to Animal Testing – here.
Once laboratory tests show no concerns, studies move into clinical science, where adult smokers are recruited to assess real-world use. These studies examine short-term safety, tolerability, performance, and acceptance. Results to-date suggest NGP can provide a satisfying alternative to cigarettes, helping reduce the desire to smoke while demonstrating encouraging short-term safety and tolerability profiles. See an example of one of our recent clinical studies here.
Perception and behavioural science assesses how NGP are understood in the real world. Research shows that both adult smokers and non-smokers recognise that NGP contain nicotine and are not risk free, but are potentially less harmful than cigarettes. Results to- also show strong appeal among adult smokers and low interest among non-smokers. Recently, heated tobacco and vape-focused Actual Use Studies (AUS) have been conducted. These longitudinal, observational studies track real adult smokers using real NGP in their daily lives, providing a close-to-real-world picture of how individuals who smoke use alternative nicotine products to help transition away from cigarettes.
Computational science supports various stages of the SAF via data modelling, helping identify trends, patterns and predict future outcomes. This can be used to assess the long-term population impact of NGP, including their potential contribution to tobacco harm reduction. Findings to-date suggest a correlation between pro-NGP regulation and reductions in smoking prevalence over time. See a recent presentation from this area of the SAF here.
Post-market surveillance collects data on how products perform once on the market in consumers’ hands. This ongoing monitoring supports the assessment of consumer safety[iii], product quality, and harm reduction potential. It also enables further scientific studies to address any remaining data gaps as products continue to be used in real-world settings.
Results from individual studies within the SAF are important, but together they provide a compelling weight of evidence demonstrating the tobacco harm reduction (THR) potential of NGP. The broad consensus of peer-reviewed scientific research, alongside in-market data on adult smoker switching and retention suggests NGP have an important role to play in contributing to global public health goals.
Frameworks like the SAF are crucial to help build and maintain trust in NGP with consumers, regulators, public health, and the media. For more information on the scientific assessment of NGP, visit Imperial Brands Science’s website.
[i] This approach is based on the concept of relative risk. Our NGP are developed for, and marketed towards, existing adult smoker and nicotine consumers only.
[ii] Toxicity Testing in the 21st Century. Read more here: https://pubmed.ncbi.nlm.nih.gov/24582757
[iii] Please note that in this context, use of the word ‘safety’ refers specifically to product quality, and isn’t intended to imply that NGPs are risk-free (i.e. ‘safe’) from the perspective of absolute harm.